Login to Your Account

FDA Panel Leans Toward More Trials For Ranexa, Doesn't Vote

By Kim Coghill

Wednesday, December 10, 2003
GAITHERSBURG, Md. - An FDA panel generally agreed that Ranexa, CV Therapeutics Inc.'s candidate for chronic angina, is approvable if the company is willing to conduct another clinical trial in a broader population that includes patients who are not resistant to traditional drugs. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription